Literature DB >> 12188968

Preliminary clinical experience with the Bryan Cervical Disc Prosthesis.

Jan Goffin1, Adrian Casey, Pierre Kehr, Klaus Liebig, Bengt Lind, Carlo Logroscino, Vincent Pointillart, Frank Van Calenbergh, Johannes van Loon.   

Abstract

OBJECTIVE: The concept of accelerated degeneration of adjacent disc levels as a consequence of increased stress caused by interbody fusion of the cervical spine has been widely postulated. Therefore, reconstruction of a failed intervertebral disc with a functional disc prosthesis should offer the same benefits as fusion while simultaneously providing motion and thereby protecting the adjacent level discs from the abnormal stresses associated with fusion. This study was designed to determine whether a new, functional intervertebral cervical disc prosthesis can provide relief from objective neurological symptoms and signs, improve the patient's ability to perform activities of daily living, decrease pain, and provide stability and normal range of motion.
METHODS: We conducted a prospective, concurrently enrolled, multicenter trial of the Bryan Cervical Disc Prosthesis (Spinal Dynamics Corp., Mercer Island, WA) for the treatment of patients with single-level degenerative disc disease of the cervical spine. Patients with symptomatic cervical radiculopathy and/or myelopathy underwent implantation with the Bryan prosthesis after a standard anterior cervical discectomy. At scheduled follow-up periods, the effectiveness of the device was characterized by evaluating each patient's pain, neurological function, and range of motion at the implanted level.
RESULTS: Analysis included data regarding 60 patients at 6 months with 30 of those patients at 1 year. Clinical success at 6 months and 1 year after implantation was 86 and 90%, respectively, exceeding the study's acceptance criteria of 85%. These results compare favorably with the short-term clinical outcomes associated with anterior cervical discectomy and fusion reported in the literature. At 1 year, there was no measurable subsidence of the devices (based on a measurement detection threshold of 2 mm). Evidence of anterior and/or posterior device migration was detected in one patient and suspected in a second patient. There was no evidence of spondylotic bridging at the implanted disc space. The measured range of motion in flexion-extension, as determined by an independent radiologist, ranged from 1 to 21 degrees (mean range of motion, 9 +/- 5 degrees). No devices have been explanted or surgically revised.
CONCLUSION: Discectomy and implantation of the device alleviates neurological symptoms and signs similar to anterior cervical discectomy and fusion. Radiographic evidence supports normal range of motion. The procedure is safe and the patients recover quickly. Restrictive postoperative management is not necessary. However, only after long-term follow-up of at least 5 years will it become clear whether the device remains functional, thus confirming these early favorable results. In addition, the influence on adjacent motion segments can be assessed after at least 5 years of follow-up.

Entities:  

Mesh:

Year:  2002        PMID: 12188968     DOI: 10.1227/00006123-200209000-00048

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  52 in total

Review 1.  Cervical spine alignment in disc arthroplasty: should we change our perspective?

Authors:  Alberto Di Martino; Rocco Papalia; Erika Albo; Leonardo Cortesi; Luca Denaro; Vincenzo Denaro
Journal:  Eur Spine J       Date:  2015-10-06       Impact factor: 3.134

2.  Cervical disc prosthesis replacement and interbody fusion: a comparative study.

Authors:  Sun Peng-Fei; Jia Yu-Hua
Journal:  Int Orthop       Date:  2006-12-16       Impact factor: 3.075

Review 3.  [Cervical disc prostheses].

Authors:  E W Fritsch; T Pitzen
Journal:  Orthopade       Date:  2006-03       Impact factor: 1.087

4.  Multidirectional flexibility analysis of anterior and posterior lumbar artificial disc reconstruction: in vitro human cadaveric spine model.

Authors:  Yoshihisa Kotani; Bryan W Cunningham; Kuniyoshi Abumi; Anton E Dmitriev; Niabin Hu; Manabu Ito; Yasuo Shikinami; Paul C McAfee; Akio Minami
Journal:  Eur Spine J       Date:  2006-03-22       Impact factor: 3.134

5.  Follow-up study on the motion range after treatment of degenerative disc disease with the Bryan cervical disc prosthesis.

Authors:  Shuhua Yang; Yong Hu; Jijun Zhao; Xianfeng He; Yong Liu; Weihua Xu; Jingyuan Du; Dehao Fu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-04

6.  Effects of a cervical disc prosthesis on maintaining sagittal alignment of the functional spinal unit and overall sagittal balance of the cervical spine.

Authors:  Seok Woo Kim; Jae Hyuk Shin; Jose Joefrey Arbatin; Moon Soo Park; Yung Khee Chung; Paul C McAfee
Journal:  Eur Spine J       Date:  2007-08-25       Impact factor: 3.134

7.  Fusion versus Bryan Cervical Disc in two-level cervical disc disease: a prospective, randomised study.

Authors:  Lei Cheng; Lin Nie; Li Zhang; Yong Hou
Journal:  Int Orthop       Date:  2008-10-28       Impact factor: 3.075

8.  Bone loss of the superior adjacent vertebral body immediately posterior to the anterior flange of Bryan cervical disc.

Authors:  Sang Hyun Kim; Young Sun Chung; Alexander E Ropper; Kyung Hoon Min; Tae Keun Ahn; Keun Soo Won; Dong Ah Shin; In Bo Han
Journal:  Eur Spine J       Date:  2015-03-19       Impact factor: 3.134

9.  Hybrid surgery of multilevel cervical degenerative disc disease : review of literature and clinical results.

Authors:  Sang-Bok Lee; Kyoung-Suok Cho; Jong-Youn Kim; Do-Sung Yoo; Tae-Gyu Lee; Pil-Woo Huh
Journal:  J Korean Neurosurg Soc       Date:  2012-11-30

10.  The NEtherlands Cervical Kinematics (NECK) trial. Cost-effectiveness of anterior cervical discectomy with or without interbody fusion and arthroplasty in the treatment of cervical disc herniation; a double-blind randomised multicenter study.

Authors:  Mark P Arts; Ronald Brand; Elske van den Akker; Bart W Koes; Wilco C Peul
Journal:  BMC Musculoskelet Disord       Date:  2010-06-16       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.